Physician profile
William Ackerman, III
NPI 1528078490
$336.70
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $84.91 · 2021: $17.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $155.11 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $45.02 | 2019 | |
| Daiichi Sankyo INC. | $32.70 | 2019 | |
| Biodelivery Sciences International, INC. | $25.06 | 2019 | |
| Baudax Bio INC. | $24.12 | 2020 | |
| Stimwave Technologies Incorporated | $18.64 | 2020 | |
| Lilly USA, LLC | $13.34 | 2020 | |
| Collegium Pharmaceutical, INC. | $11.66 | 2019 | |
| Eisai INC. | $11.05 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.